APP and Alzheimer disease: GLT-1 (EAAT2 in human), the dominant glutamate transporter in the cerebral cortex and hippocampus, is significantly reduced in AD patients and mice (Pereira et al., 2017; Sharma et al., 2019), and increased GLT-1 level by Cef treatment was associated with improved cognitive ability in APP/PS1 mice (Fan et al., 2018).